
|Articles|April 15, 2002
Comfort level of ocular allergy agent is key to patient compliance
San Antonio, TX-A treatment for seasonal allergic conjunctivitis, pemirolast potassium 0.1% ophthalmic solution (Alamast, Santen Inc., Napa, CA), was shown to be more comfortable for patients and equally effective when used twice a day during ragweed season when compared with nedocromil sodium 2% ophthalmic solution (Alocril, Allergan, Irvine, CA). These two drugs are the two latest mast-cell stabilizers that have become commercially available to treat ocular allergies.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
PolyActiva and RareSight partner to develop treatments for rare pediatric retinal diseases
2
What ‘I’m Fine’ Really Means: An Open Letter from a Thyroid Eye Disease (TED) Patient
3
Opus Genetics has Type B RMAT meeting with FDA for its gene therapy candidate, OPGx-LCA5
4
AAO 2025: A study of retinal vasculitis events with intravitreal agents
5


















































.png)


